Knight Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and distributing innovative prescription pharmaceuticals, consumer health products and medical devices in Canada and Latin America. Knight is publicly traded on the TSX (GUD).
Suite 1055
Montreal, QC Canada H3Z 3B8
President and CEO
info@knighttx.com
| Company | Analyst | |
| Bloom Burton | David Martin | dmartin@bloomburton.com |
| Canaccord Genuity | Tania Gonsalves | TGonsalves@cgf.com |
| Mackie Research | Andre Uddin | auddin@mackieresearch.com |
| National Bank | Endri Leno | endri.leno@nbc.ca |
| Paradigm Capital | Scott McAuley | smcauley@paradigmcap.com |
| Raymond James | Rahul Sarugaser | rahul.sarugaser@raymondjames.com |
| RBC Capital Markets | Douglas Miehm | douglas.miehm@research.rbccm.com |
| Stifel GMP | Justin Keywood | jkeywood@stifel.com |